Dual-Allergen Exposure Hypothesis

The idea. The dual-allergen exposure hypothesis was proposed by Gideon Lack (King’s College London / Guy’s and St Thomas’). It says the route of first exposure decides whether a child becomes allergic to a food or tolerant of it. Low-dose contact through inflamed, leaky eczematous skin, for example peanut protein in house dust or on parents’ hands, or peanut-oil creams, encourages IgE sensitisation through a Th2 Immune Response. Early, regular eating of the same food induces oral tolerance (Papapostolou 2022). It explains why eczema, especially early-onset and severe eczema, usually comes before food allergy, and why eczema is the strongest risk factor for it. In this model, food allergy is mainly a consequence of eczema rather than its cause. It also predicts that avoiding a food while the skin stays inflamed is the worst combination.

Skin Barrier Dysfunction [causes] Food Allergy Dual-Allergen Exposure Hypothesis [defines] Atopic March Peanut Oil Sensitisation [supports] Dual-Allergen Exposure Hypothesis

Evidence: LEAP and EAT. The LEAP Trial (Du Toit et al., NEJM 2015) randomised 640 high-risk infants aged 4–11 months with severe eczema and/or egg allergy to eat or avoid peanut until age 5. In those with a negative skin test at entry, peanut allergy was 13.7% with avoidance against 1.9% with eating it, an 86% relative reduction. Peanut levels in bed dust were measured too: avoiders’ beds still contained peanut (median 4.1 µg/g dust), so they had skin and environmental exposure without oral exposure. Avoiders more often had raised peanut-specific IgE. The EAT Trial (Perkin et al., NEJM 2016) tested early introduction of six allergenic foods from 3 months in 1,303 breastfed infants from the general population. The intention-to-treat result was not significant (5.6% vs 7.1%). Among children who actually ate the foods (per protocol), food allergy fell from 7.3% to 2.4%, peanut allergy from 2.5% to 0%, and egg allergy from 5.5% to 1.4%. Observational links between peanut-oil creams and peanut allergy (Lack 2003) and between oat creams on eczematous skin and oat sensitisation (Boussault 2007) support the skin-sensitisation half of the idea.

LEAP Trial [supports] Dual-Allergen Exposure Hypothesis EAT Trial [supports] Dual-Allergen Exposure Hypothesis Colloidal Oatmeal [relates] Dual-Allergen Exposure Hypothesis

Conflict: [Perkin et al., EAT, NEJM 2016] says early introduction of six allergens “did not show efficacy… in an intention-to-treat analysis” in general-population infants. [BSACI early-introduction guidance, 2018] says early introduction of egg and peanut “may help prevent development of food allergy”. The guidance rests mainly on per-protocol EAT data and on LEAP in high-risk infants. How far the benefit generalises to low-risk infants, and to foods other than egg and peanut, remains unresolved — add to open_questions.

Guidance that follows from it: NIAID 2017 addendum (US). The NIAID-sponsored panel (Togias et al., JACI 2017; summarised by the American Academy of Dermatology) issued three risk-tiered recommendations. (1) Infants with severe eczema and/or egg allergy: consider peanut-specific IgE and/or Skin Prick Testing, then introduce peanut-containing foods at 4–6 months, at home or under supervision depending on the result. Wheals of 3–7 mm need a supervised feed or Oral Food Challenge; ≥8 mm likely means existing allergy and needs specialist care. (2) Mild–moderate eczema: introduce peanut around 6 months, no testing needed. (3) No eczema or food allergy: introduce peanut according to family and cultural preferences. The panel explicitly does not recommend panel testing for other foods because of poor positive predictive value. For LEAP’s skin-test-negative infants, the number needed to treat to prevent one case of peanut allergy was 8.5.

Dual-Allergen Exposure Hypothesis [supports] American Academy of Dermatology Skin Prick Testing [relates] Dual-Allergen Exposure Hypothesis

UK guidance: BSACI (2018). The British Society for Allergy and Clinical Immunology and the BDA Food Allergy Specialist Group advise that “higher-risk” infants (those with eczema or an existing food allergy) may benefit from starting solids from 4 months. Egg and then peanut, in age-appropriate forms, should go in once the baby is already taking purées, and keep being offered regularly. Excluding egg and peanut “could increase their risk of food allergy”, so they should be introduced before 1 year if they are part of the family diet. BSACI warns that waiting for allergy testing can itself delay introduction and raise risk. It notes that even in severe eczema, anaphylaxis on first introduction is rare (1–2 per 1,000). Infants with moderate–severe or very early-onset (<3 months) eczema have the highest risk of reacting, and their parents should speak to a health professional first. For toddlers aged 1–4 who already have eczema, the practical message is to keep eating tolerated allergenic foods regularly and to control the skin. Unsupervised Elimination Diets work against both.

Dual-Allergen Exposure Hypothesis [opposes] Elimination Diets Emollient Therapy [relates] Dual-Allergen Exposure Hypothesis

Connections

• Skin Barrier Dysfunction — explains why eczema precedes food allergy, source: Papapostolou, J Clin Med 2022
• Peanut Oil Sensitisation — peanut-oil creams on inflamed skin linked to peanut allergy, source: Lack 2003
• Colloidal Oatmeal — oat creams on eczematous skin linked to oat sensitisation, source: Boussault 2007
• LEAP Trial — key RCT: early peanut eating cut allergy 13.7%→1.9%, source: Du Toit 2015
• EAT Trial — general-population early introduction; per-protocol benefit only, source: Perkin 2016
• Food Allergy — explains eczema→food allergy direction, source: Papapostolou 2022; Braun 2025
• Elimination Diets — avoidance with ongoing skin exposure favours allergy, source: Chang 2016
• American Academy of Dermatology — summarises NIAID 2017 addendum tiers, source: AAD
• Th2 Immune Response — skin-route sensitisation pathway, source: Papapostolou 2022
• Almond Oil — almond oil on AD infant skin → almond IgE without ingestion, source: Guillet 2000
• Tree Nut Allergy — nut-containing skin products as cutaneous route, source: Guillet 2000; Adomaite 2020